Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial

The IL-33/ST2 pathway is linked with asthma susceptibility. Inhaled allergens, pollutants, and respiratory viruses, which trigger asthma exacerbations, induce release of IL-33, an epithelial-derived “alarmin.” Astegolimab, a human IgG2 mAb, selectively inhibits the IL-33 receptor, ST2. Approved biol...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of allergy and clinical immunology Vol. 148; no. 3; pp. 790 - 798
Main Authors:	Kelsen, Steven G., Agache, Ioana O., Soong, Weily, Israel, Elliot, Chupp, Geoffrey L., Cheung, Dorothy S., Theess, Wiebke, Yang, Xiaoying, Staton, Tracy L., Choy, David F., Fong, Alice, Dash, Ajit, Dolton, Michael, Pappu, Rajita, Brightling, Christopher E.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.09.2021
Subjects:	asthma exacerbations eosinophils IL-33 severe asthma ST2 ST2 asthma exacerbations Feno AE SAE severe asthma ICS eosinophils IL-33 AER T2
ISSN:	0091-6749, 1097-6825, 1097-6825
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!